Iovance Biotherapeutics, Inc.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
Find out what a historical investment in Iovance Biotherapeutics, Inc. would be worth today using our IOVA stock calculator.
$1.41B
-
0.00%
9.8M
$3.49
$3.28
$3.42
$5.63
$1.64
Ready to start your investing journey with Stake?
Open an accountIOVA FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in IOVA
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in IOVA
on Stake
Buy IOVA from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of IOVA from only US$10 with fractional shares
